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Diagnosis of Epstein-Barr virus (EBV) infection is based on clinical symptoms and serological markers,
including the following: immunoglobulin G (IgG) and IgM antibodies to the viral capsid antigen (VCA),
heterophile antibodies, and IgG antibodies to the EBV early antigen-diffuse (EA-D) and nuclear antigen
(EBNA-1). The use of all five markers results in 32 possible serological patterns. As a result, interpretation of
EBV serologies remains a challenge. The purpose of this study was to use a large population of patients to
develop evidence-based tools for interpreting EBV results. This study utilized 1,846 serum specimens sent to
the laboratory for physician-ordered EBV testing. Chart review was performed for more than 800 patients, and
diagnoses were assigned based on physician-ordered testing, clinical presentation, and patient history. Testing
for all five EBV antibodies was performed separately on all serum samples using the Bio-Rad BioPlex 2200
system. Presumed EBV diagnosis (based on previous publications) was compared to EBV diagnosis based on
a medical record review for each serological pattern. Interestingly, of the 32 possible serological patterns, only
12 occurred in >10 patients. The remaining 20 patterns were uninterpretable because they occurred with such
infrequency. Two easy-to-use tables were created to interpret EBV serological patterns based on whether three
(EBV VCA IgG, IgM, and heterophile) or five markers are utilized. The use of these two tables allows for
interpretation of >95% of BioPlex serological results. This is the first evidence-based study of its kind for EBV
serology.
Epstein Barr virus (EBV) is a gammaherpesvirus that causes
a number of clinical syndromes, including acute mononucleosis
and posttransplant lymphoproliferative disease, and has been
linked to a number of malignancies (6). Most people have been
exposed to EBV by early adulthood. After the initial infection,
the virus becomes latent in B lymphocytes, and it can reactivate
later in life to produce posttransplant lymphoproliferative dis-
ease in immunocompromised transplant patients, central ner-
vous system lymphoma in AIDS patients, or a more classic
acute EBV-related viral illness in some patients infected with
other viruses (6).
Acute infection with EBV can vary widely with regard to the
severity and presentation of illness, ranging from an asymp-
tomatic infection to a serious, life-threatening version of
mononucleosis with associated liver damage and splenomegaly
(6). Additionally, other acute viral syndromes, including those
caused by hepatitis viruses and cytomegalovirus (CMV), can
lead to similar clinical syndromes. The variety of symptoms and
the overlap with other viral infections underscore the impor-
tance of laboratory testing in the diagnosis of acute EBV-
related disease. Serological markers for EBV infection have
been and remain the most commonly used diagnostic tools for
this purpose.
Assays using immunoglobulin G (IgG) and IgM antibodies
to the viral capsid antigen (VCA) and heterophile antibodies
(IgM) are the most commonly performed EBV serological
tests. IgG antibodies to EBV early antigen-diffuse (EA-D) and
nuclear antigen (EBNA-1) can also be performed. If all five
antibodies are measured, there are 32 possible serological pat-
terns that could be generated (Table 1). The presumed diag-
noses shown in Table 1 are derived from various sources (5, 6,
11). However, there is disagreement on the assignment of
certain patterns. Thus, despite our experience with these diag-
nostic tests, interpretation of EBV serological patterns remains
a challenge (4).
Bio-Rad Laboratories (Hercules, CA) recently introduced a
multiplex platform (BioPlex 2200) that can measure all five of
these antibodies from one sample in two reaction vessels. We
and others recently evaluated this platform with regard to its
performance against various predicate assays and showed that
it performed quite well (3, 7).
The purpose of this study was to use a large population of
patients to develop evidence-based, easy-to-use tables for in-
terpreting multiplexed EBV results. To our knowledge this
study is the first of its kind.
MATERIALS AND METHODS
Patient samples and EBV testing. Two thousand sixty-four consecutive serum
specimens sent to the Barnes-Jewish Hospital and St. Louis Children’s Hospital
laboratories for physician-ordered EBV testing from 13 October 2004 to 28
December 2007 were utilized. The patient population represents both inpatients
and outpatients and a large number of pre- and posttransplant patients, as well
as specimens from tertiary physicians’ offices. Specimens were frozen for up to 30
months at 70°C, thawed, and analyzed immediately. Testing for all five anti-
bodies was performed with the IgG (EBV VCA, EBV EA-D, and EBV NA) and
* Corresponding author. Mailing address: Department of Pathology
and Immunology, Washington University School of Medicine, 660 S.
Euclid, Box 8118, St. Louis, MO 63110. Phone: (314) 362-0194. Fax:
(314) 362-1461. E-mail: gronowski@wustl.edu.
 Published ahead of print on 5 August 2009.
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IgM (EBV VCA and heterophile) assays on the BioPlex 2200 automated plat-
form according to the manufacturer’s instructions. These assays have been FDA
cleared, and cutoffs for positive, negative, and equivocal were established previ-
ously by the manufacturer; these cutoffs were used in this study. Two hundred
eighteen specimens were excluded. One hundred forty-five of 2,064 specimens
were excluded due to 1 equivocal BioPlex result (note: 5 of the 145 specimens
had 2 equivalent results; therefore, 150 equivocals/10,320 total results  1.5%
equivocal results observed). Forty-seven specimens were excluded due to an
insufficient quantity of sample for testing. Twenty-six were excluded due to
insufficient patient identification associated with the sample. Of the remaining
1,846 specimens in the study, the ages ranged from 1 year of age to 90 years
of age, with approximately 45% of patients under the age of 20.
Physician-ordered EBV testing. EBV anti-VCA IgG, EBV anti-VCA IgM, and
anti-EBNA-1 IgG assays were performed using the Captia assay (Trinity Biotech
USA, Jamestown, NY) as described in the manufacturers’ package inserts on the
Dynex DSX (Chantilly, VA) automated platform. The Status Mono (LifeSign
LLC, Somerset, NJ) heterophile antibody assay was performed as described in
the manufacturer’s package insert.
Chart review and classification of disease state. One physician, who was
blinded to the BioPlex results, reviewed all medical records. Case summaries
were recorded on standardized forms, and the information gathered included
physician-ordered EBV and CMV serologies, patient history, pertinent physical
exam findings including fever, lymphadenopathy, pharyngitis, rash, malaise, or
hepatosplenomegaly, results of manual and automated complete blood count,
and results of any concurrent microbiological testing. Using all the clinical and
laboratory data available, the physician reviewer assigned each patient to one of
five possible EBV diagnoses (EBV naive, primary acute, past infection, recovery/
reactivation, or unknown).
Patients were determined to be EBV naive when they had negative VCA IgG,
EA-D, and/or EBNA-1 results and either no IgM or heterophile antibody or no
clinical suspicion of acute infection.
Primary acute infection was predominantly associated with the presence of
fatigue, malaise, low-grade fever, cervical lymphadenopathy, pharyngeal symp-
toms with or without a tonsillar exudate, a maculopapular or morbilliform rash,
hepatosplenomegaly or elevation in liver enzymes, and elevation in mononuclear
cells and atypical lymphocytes. The absence of another appropriate diagnosis and
the presence of appropriate acute serologies (IgM and heterophile antibody)
were considered but were not necessary for the diagnosis of acute EBV infection.
Past infection patients were defined as those with any positive IgG serology to
VCA or EBNA-1 without suspicion of acute infection.
Recovery was defined as positive acute serology or residual symptoms at
greater than 2 weeks from onset. Reactivation was considered an occurrence of
what appeared to be acute infection in a patient known to be seropositive for
VCA IgG and/or EBNA-1 IgG.
The “unknown” category was reserved for patients who could not be assigned
to one of the other categories and had conflicting clinical and serological pic-
tures.
For the two most common serological patterns, corresponding to naive and
past infection (patterns 1 and 12), the reviewer was given only 20% of patients’
medical records to review. Washington University School of Medicine Institu-
tional review board approval was obtained prior to initiation of this study.
Statistics. Sensitivities, specificities, predictive values, odds ratios, and P values
along with all 95% confidence intervals were calculated using Prism software
(Prism Software Corporation, Irvine, CA).
RESULTS
BioPlex EBV testing was performed on 1,846 specimens.
The prevalence of all 32 possible serological patterns is shown
in Tables 2 and 3. Of the 32 possible serological patterns that
could have resulted, 10 patterns did not occur in any of the
1,846 specimens and another 10 patterns occurred in 10 of
the 1,846 specimens. Few conclusions can be drawn about the
serological patterns that occur with such infrequency. For this
reason, the data are split into patterns that were observed in
10 patients (Table 2) and patterns that were observed in10
patients (Table 3). Also shown for each BioPlex EBV serolog-
ical pattern is the EBV diagnosis based on a medical record
review. A medical record review was performed for all patients
with the exception of patients with patterns 1 and 12 in Table
2, where a representative 20% of patients were reviewed. In
Table 2, the concordance between presumed EBV diagnosis
and evidence-based EBV diagnosis is shown by the bolded
numbers. Predictive values are also calculated and shown. No
calculations were made on the data in Table 3, since it is
difficult to draw conclusions with regard to the association of
any of these patterns with EBV diagnosis with such small
numbers of patients.
The goal of this study was to develop evidence-based easy-to-
use tables for interpreting multiple EBV results. To do this, all
EBV patterns with predictive values of 50% were removed
from Table 2 (patterns 2, 29, and 30). Table 4 shows the
remaining nine serological patterns that had sufficiently high
predictive values to consider them associated with a particular
EBV diagnosis, along with calculated diagnostic parameters
for each verified pattern. Of note, three patterns (15, 17, and
22) that were presumed to indicate recovery/reactivation were
TABLE 1. All possible serological patterns and presumed EBV
diagnoses based on published reportsa
Pattern
no.
“Presumed”
EBV stagea,b
EBV serological patternc
VCA
IgG
EBNA-1
IgG
EA-D
IgG
VCA
IgM
Heterophile
IgM
1 EBV naive Neg Neg Neg Neg Neg
2 Primary acute Neg Neg Neg Pos Neg
3 Primary acute Pos Neg Neg Pos Neg
4 Primary acute Neg Neg Pos Pos Neg
5 Primary acute Neg Neg Neg Pos Pos
6 Primary acute Pos Neg Neg Neg Pos
7 Primary acute Pos Neg Pos Pos Neg
8 Primary acute Pos Neg Neg Pos Pos
9 Primary acute Neg Neg Pos Pos Pos
10 Primary acute Pos Neg Pos Neg Pos
11 Primary acute Pos Neg Pos Pos Pos
12 Past infection Pos Pos Neg Neg Neg
13 Past infection Neg Pos Pos Neg Neg
14 Past infection Pos Neg Neg Neg Neg
15 Recov/React Pos Pos Pos Neg Neg
16 Recov/React Neg Pos Neg Pos Neg
17 Recov/React Pos Pos Neg Pos Neg
18 Recov/React Neg Pos Pos Pos Neg
19 Recov/React Neg Pos Neg Pos Pos
20 Recov/React Pos Pos Neg Neg Pos
21 Recov/React Neg Pos Pos Neg Pos
22 Recov/React Pos Pos Pos Pos Neg
23 Recov/React Pos Pos Neg Pos Pos
24 Recov/React Neg Pos Pos Pos Pos
25 Recov/React Pos Pos Pos Neg Pos
26 Recov/React Pos Pos Pos Pos Pos
27 Unknown Neg Neg Pos Neg Neg
28 Unknown Neg Neg Neg Neg Pos
29 Unknown Neg Pos Neg Neg Neg
30 Unknown Pos Neg Pos Neg Neg
31 Unknown Neg Neg Pos Neg Pos
32 Unknown Neg Pos Neg Neg Pos
a See references 5, 6, and 11.
b Recov/React, recovery/reactivation: those patients who are in a late acute
infection stage or have benign reactivation.
c Pos, positive; Neg, negative.
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actually determined to indicate past infection based on the
evidence-based diagnosis. Also, to properly calculate the sen-
sitivity, the numbers for the serological patterns were adjusted
in Table 4 to include those patients whose cases were not
reviewed. For example, for pattern 12, the 710 patients whose
data were not reviewed (see Table 2) were distributed into the
five EBV diagnosis groups based on the relative frequencies of
occurrence in the representative 182 patients with that pattern
TABLE 2. Serological patterns and EBV diagnosis for the 12/32 serological patterns that occurred in 10 patientsa
Patternb
no.
“Presumed”
EBV diagnosis
BioPlex 2200 resulth
No. of patients
Predictivef
value (%)In
study
With EBV diagnosis based on medical record reviewc
Not
reviewedVCA
IgG
EBNA-1
IgG
EA-D
IgG
VCA
IgM
Het
IgM
EBV
naive
Primary
acute
Past
infection
Recovery/
reactivation Inconclusive
1 EBV naive Neg Neg Neg Neg Neg 401 57 0 5 0 21 318d 68.7
2 Primary acute Neg Neg Neg Pos Neg 17 7 6 3 1 0 0 35.3
4 Primary acute Neg Neg Pos Pos Neg 10 0 4 1 0 2 3e 57.1
5 Primary acute Neg Neg Neg Pos Pos 14 0 13 0 1 0 0 92.9
9 Primary acute Neg Neg Pos Pos Pos 20 0 18 0 0 2 0 90.0
12 Past infection Pos Pos Neg Neg Neg 892 1 0 171 1 9 710d 94.0
14 Past infection Pos Neg Neg Neg Neg 33 2 1 22 1 7 0 66.7
15 Recov/React Pos Pos Pos Neg Neg 306 3 0 232 0 63 8e N/Cg
17 Recov/React Pos Pos Neg Pos Neg 56 1 0 42 0 13 0 N/C
22 Recov/React Pos Pos Pos Pos Neg 25 1 1 20 1 2 0 N/C
29 Unknown Neg Pos Neg Neg Neg 24 12 0 6 0 5 1e N/C
30 Unknown Pos Neg Pos Neg Neg 12 0 1 6 0 5 0 N/C
Total 1,810 84 44 508 5 129 1,040
a Shown are the 12/32 possible serological patterns that occurred in 10 patients.
b Pattern numbers correspond to those shown in Table 1.
c See Materials and Methods for classification of EBV stage. Areas of expected concordance between the “presumed” and observed EBV stage are highlighted in bold.
d Twenty percent of randomly selected patients were reviewed.
e Patients were not reviewed due to unavailability of the medical record.
f Predictive value was calculated by dividing the number of patients highlighted in bold by the total number of patients with completed chart review in that row.
g N/C, not calculated. See Discussion.
h Pos, positive; Neg, negative.
TABLE 3. Serological patterns and EBV diagnosis for the 20/32 serological patterns that occurred in 10 patientsa
Pattern
no.b
“Presumed”
EBV stage
BioPlex 2200 resultc
No. of patients
In
study
With EBV diagnosis based on medical record reviewd
VCA
IgG
EBNA-1
IgG
EA-D
IgG
VCA
IgM
Het
IgM
EBV
naive
Primary
acute
Past
infection
Recovery/
reactivation Inconclusive
3 Primary acute Pos Neg Neg Pos Neg 7 0 2 3 1 1
6 Primary acute Pos Neg Neg Neg Pos 0 0 0 0 0 0
7 Primary acute Pos Neg Pos Pos Neg 2 0 0 0 1 1
8 Primary acute Pos Neg Neg Pos Pos 1 0 1 0 0 0
10 Primary acute Pos Neg Pos Neg Pos 0 0 0 0 0 0
11 Primary acute Pos Neg Pos Pos Pos 4 0 2 0 1 1
13 Past infection Neg Pos Pos Neg Neg 6 3 1 0 0 2
16 Recov/Reacte Neg Pos Neg Pos Neg 0 0 0 0 0 0
18 Recov/React Neg Pos Pos Pos Neg 0 0 0 0 0 0
19 Recov/React Neg Pos Neg Pos Pos 0 0 0 0 0 0
20 Recov/React Pos Pos Neg Neg Pos 0 0 0 0 0 0
21 Recov/React Neg Pos Pos Neg Pos 0 0 0 0 0 0
23 Recov/React Pos Pos Neg Pos Pos 1 0 0 1 0 0
24 Recov/React Neg Pos Pos Pos Pos 0 0 0 0 0 0
25 Recov/React Pos Pos Pos Neg Pos 0 0 0 0 0 0
26 Recov/React Pos Pos Pos Pos Pos 4 0 2 2 0 0
27 Unknown Neg Neg Pos Neg Neg 7 4 1 1 1 0
28 Unknown Neg Neg Neg Neg Pos 1 0 1 0 0 0
31 Unknown Neg Neg Pos Neg Pos 3 0 2 0 0 1
32 Unknown Neg Pos Neg Neg Pos 0 0 0 0 0 0
Totals: 36 7 12 7 4 6
a Shown are the 20/32 possible serological patterns that occurred in 10 patients.
b Pattern numbers correspond to those shown in Table 1.
c Pos, positive; Neg, negative.
d See Materials and Methods for classification of EBV stage.
e Recov/React, recovery/reactivation: those patients who are in a late acute infection stage or have benign reactivation.
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that were reviewed. Since 171/182 (94%) of patients were di-
agnosed as “past infection,” 94% of the 710 nonreviewed pa-
tients (667 patients) were added to the “past infection” cate-
gory for Table 4. The remaining 43 nonreviewed patients were
distributed to the other various diagnostic categories in the
same manner.
Because it is common practice for physicians to order only
the VCA IgG and IgM and the heterophile antibodies to de-
termine the EBV disease stage or serological status of patients,
Table 5 illustrates the frequencies of those eight possible se-
rological patterns in our patient population. The predictive
values for patients correctly identified by serology were calcu-
lated as they were in Table 2. The four of eight possible
patterns with predictive values of 50% and sufficient num-
bers of patients are shown in Table 6, along with calculations of
combined predictive values and sensitivities. Similar to Table
4, patients whose records were not reviewed were included in
Table 6 based on pattern frequencies for patients whose
records were reviewed in Tables 2 and 3.
DISCUSSION
The diagnosis of EBV-related disease is based on clinical
symptoms and laboratory testing. The importance of serolog-
ical testing for EBV-related disease cannot be underestimated.
However, the association between a particular EBV diagnosis
and serological patterns is based largely on assumptions. While
utilization of multiplex technology for the detection of EBV
antibodies has been evaluated recently (1, 3, 7, 9, 12), this is the
first evidence-based study of its kind aiming to match a large
number of clinical diagnoses with EBV serological patterns.
Here, we analyzed almost 1,850 specimens, generating
10,000 individual serological test results, and reviewed the
medical records of more than 800 patients.
Of the 1,846 specimens that were analyzed in this study, 98%
(1,810/1,846) had one of only 12 different serological patterns
(Table 2). The 20 remaining patterns (Table 3) were so un-
common that it is not possible to make a conclusion as to their
association with a particular EBV diagnosis. Among the pat-
terns that were not common (Table 3) were those that were
VCA IgG positive along with other positive markers of a pri-
mary acute infection (VCA IgM, EA-D IgG, and/or hetero-
phile; pattern numbers 3, 6, 7, 8, 10, and 11). It has been
classically assumed that VCA IgG would be positive in a large
percentage of patients positive for VCA IgM and/or hetero-
phile antibodies (5, 6), but this was not observed in this pop-
ulation. A likely reason for this difference is that the BioPlex
assay was developed with the expectation that the IgG and IgM
kits would be used together. The VCA IgG assay detects an-
tibodies to the EBV p18 antigen, which was previously shown
to be a late marker of infection (2). Thus, the BioPlex VCA
IgG assay is less likely to be positive for patients with early
acute infections.
Another observation based on the data in Table 2 is that the
cases with patterns presumed to be recovery/reactivation (pat-
terns 15, 17, and 22) were actually determined to be past
infection by chart review. Records of many of these patients
were subjected to unblinded rereview, and even with the
knowledge of their entire EBV serological pattern, almost all
were still considered to be in the past-infection stage. This
would suggest that the vast majority of patients with these
three patterns could be clinically considered to have past in-
fection with no suggestion of a current EBV-related disease
process. It is possible that many of these patients had benign
reactivation of EBV. In patients that harbor latent EBV, the
virus can reactivate. However, in immunocompetent patients,
this reactivation typically does not progress to the lytic stage of
viral replication and has little to no clinical consequence (10).
Thus, during a chart review of the patient’s symptoms and
other clinical data, there would be no evidence of an active
process, but the patient would show evidence of past infection.
Calculations of the predictive values shown in Tables 2 and 5
were not performed for these patterns, since these calculations
TABLE 5. Serological patterns and EBV diagnoses for the 1,846 study patients using only BioPlex VCA IgG, VCA IgM, and heterophile
antibody assay results
Pattern
designation
“Presumed”
EBV diagnosis
BioPlex resultb
No. of patients
Predictive
value (%)fIn study
With EBV diagnosis based on medical record reviewc
Not
reviewedVCA
IgG
VCA
IgM
Het
IgM
EBV
naive
Primary
acute
Past
infection
Recovery/
reactivation Inconclusive
A EBV naive Neg Neg Neg 438 76 2 12 1 28 319d 63.9
B Primary acute Neg Pos Pos 34 0 31 0 1 2 0 91.2
C Primary acute Neg Pos Neg 27 7 10 4 1 2 3e 41.7
D Primary acute Neg Neg Pos 4 0 3 0 0 1 0 75.0
E Past infection Pos Neg Neg 1,243 6 2 431 2 84 718d 82.1
F Recov/Reacta Pos Pos Neg 90 2 3 65 3 17 0 N/Cg
G Recov/React Pos Pos Pos 10 0 5 3 1 1 0 N/C
H Recov/React Pos Neg Pos 0 0 0 0 0 0 0 N/C
Total 1,846 91 56 515 9 135 1,040
a Recov/React, recovery/reactivation: those patients who are in a late acute infection stage or have benign reactivation.
b Pos, positive; Neg, negative.
c See Materials and Methods for classification of EBV stage. Areas of expected concordance between “Presumed” and observed EBV stage are highlighted in bold.
d Records of a percentage of randomly selected patients were reviewed (see Table 2).
e Patients were not reviewed due to unavailability of the medical record.
f Predictive value calculated by dividing the number of patients in the shaded box by the total number of patients with completed chart review in that row.
g N/C, not calculated. See Results and Discussion.
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would assume that the presumed stage is the correct assign-
ment for these patterns. For Table 4, patterns 15, 17, and 22
were included in the calculations of combined sensitivity and
predictive value to predict past infection rather than recovery/
reactivation.
As we previously described, the heterophile assay on the
BioPlex platform is different from standard latex agglutination
heterophile assays in that it detects only IgM antibodies, has a
numerical rather than visual cutoff, and utilizes purified horse
red blood cell antigen rather than bovine antigen (8). In that
report, we utilized a data set different from that presented here
and showed that the BioPlex heterophile assay adds diagnostic
value for both adults and children (8). It is evident from Tables
2 and 5 in the current study that the heterophile assay does
indeed improve the predictive value for the diagnosis of acute
infection. Comparing patterns 2 and 5 within Table 2, patterns
4 and 9 within Table 2, and patterns B and C within Table 5,
the predictive value for diagnosing acute infection is signifi-
cantly higher if the patient has a positive heterophile antibody.
One additional reason for this finding is that we have shown
previously that there are other causes for a false-positive VCA
IgM result, especially acute infection with CMV or Toxoplasma
(8). Thus, most of the patients that had pattern 2 in Table 2
likely had one of these conditions and did not have a primary
acute EBV infection. However, a false-positive VCA IgM re-
sult is much less likely in the setting of a concurrently positive
heterophile assay.
The nine patterns represented in Table 4 are the most com-
mon and have high enough associations with an EBV stage to
be considered indicative of those respective stages. Interest-
ingly, these patterns could be used to diagnose more than 95%
of the patients in this study (1,757/1,846 patients) with good
diagnostic accuracy. In our patient population, we had patients
being evaluated for acute disease and for pretransplant sero-
logical status. As a result, the diagnostic utility shown in Tables
4 and 6 may differ if the patient demographics are significantly
different (e.g., mostly acutely ill pediatric patients and few
pretransplant patients). This should be kept in mind when
extrapolating our data to other centers.
IgG and IgM antibodies to VCA and heterophile antibodies
are commonly the only three antibodies tested in clinical prac-
tice for determination of EBV status or for diagnosing acute
EBV-related disease. Shown in Table 5 are the eight possible
serological patterns using only these three antibodies. Table 6
displays calculations using the most common patterns (similar
to those shown in Table 4) and only these three antibodies.
Comparing sensitivities and predictive values between Tables 4
and 6 suggests that using all five antibodies provides better
sensitivity for diagnosing primary acute EBV infection, since
only 53% of patients determined to have primary acute infec-
tion were identified using the three analytes, compared to 64%
when all five antibodies are utilized. One of the primary rea-
sons for this is the higher predictive value seen when patients
have both positive VCA IgM and EA-D IgG antibodies com-
pared to only positive VCA IgM (see Table 2, patterns 2 and
4). In Table 5, pattern C contains both EA-D IgG-positive and
-negative patients, and the predictive value for that pattern
(41.7%) is not sufficient to consider it associated with primary
acute disease. In contrast, pattern 4 in Table 2 did have suffi-
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cient predictive value and was able to be included in the cal-
culations of sensitivity in Table 4.
Predictive values when three antibodies were used to predict
EBV diagnosis were similar to predictions made using all five
analytes. One likely reason for this stems from the perfor-
mance of the BioPlex VCA IgG assay, as discussed above.
Since the BioPlex VCA IgG has a strong association with past
infection and is thus unlikely to be positive in patients with
early acute disease, it is therefore not as essential to perform
the EBNA-1 IgG assay to verify that the patient is indeed in
the past-infection stage. In addition, except for the relatively
small number of patients with a primary acute EBV infection,
EA-D IgG was of little utility. Concerning predictive values, it
should be noted that these values are dependent on the prev-
alence of EBV disease in the given population. At our institu-
tion, we test pre- and posttransplant patients, thus lowering
our overall prevalence of acute EBV disease. Centers should
take this into account when applying these tables to their
patient population and adjust for their prevalence.
It should be noted that, as described above, there are dif-
ferences in the VCA-IgG and heterophile antibody assays on
the BioPlex 2200 platform compared to other assays. This
suggests that the interpretive patterns shown here are specific
to use with BioPlex results. However, in this study and two
previous studies (3, 7), there was very strong (92 to 97%)
concordance between BioPlex 2200 and predicate assay results.
Therefore, Tables 4 and 6 may also be useful for interpretation
of EBV serologic results generated with other assays, but fur-
ther studies obviously are needed to support that hypothesis.
Based on these data, we recommend an evidence-based ap-
proach to the interpretation of BioPlex EBV serological pat-
terns. We suggest the use of Table 4 to interpret the serological
patterns when five serological tests are ordered, and because of
the better sensitivity observed, we further recommend testing
all five antibodies when trying to diagnose primary acute EBV
disease. We also provide Table 6 to be used when only EBV
VCA IgG, IgM, and heterophile antibodies are ordered and
suggest that testing of only these three antibodies is sufficient
when trying to simply establish the EBV serologic status of a
patient. We feel that only patterns that appear in these tables
can be interpreted with confidence, since there are not enough
data to support the interpretation of other serological patterns.
We do not propose or recommend the isolated use of these
tables in the diagnosis of EBV-related disease, but we suggest
that this represents an evidence-based tool to be used in con-
junction with other laboratory and clinical parameters for the
classification of the EBV disease stage.
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